About Algonist
1.5 BILLION
PEOPLE AFFECTED GLOBALLY WITH CHRONIC PAIN
Chronic pain affects 1 in 5 people globally, but this remains a major unmet medical need as patients fail to find adequate relief with standard analgesic treatments.
Algonist is a privately owned pre-clinical stage biotechnology company founded by an experienced team of drug developers, business professionals and scientists, developing novel small molecule drugs to treat chronic pain.
Our mission is to develop drugs with similar potency to opioids but without leading to addiction.
The Chronic Pain Problem
Chronic pain is the leading cause of long term-disability in the U.S.
(National Institute of Health)
50 million Americans live with chronic pain. (CDC)
8% of Americans suffer from high-impact, long lasting pain
(National Institute of Health)
50% of cancer patients experience chronic pain
(International Association for the Study of Pain, 2008)
500 million working days are lost in Europe due to chronic pain with an annual cost of €300B (European Pain Foundation)
People with chronic pain consider suicide twice as often
(US Pain Foundation)
Key Algonist Facts
• Oral small molecules targeting promising chronic pain targets.
• Panel of drug candidates with in vitro and in vivo proof-of-concept obtained.
• Ongoing discovery of novel drug classes identified using a powerful in silico drug discovery approach.
• Highly experienced biotech team and world-leading scientific collaborators.
• Originating research from world-renowned pharmacology academic group from the Medical Faculty at the University of Pecs, Hungary.
• Founded in 2020, located in the CEBINA biotech incubator/accelerator in Vienna, Austria.
Management Team
Advisors
Partners
